Arrowstreet Capital
REGN icon

Arrowstreet Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Arrowstreet Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245M Buy
393,685
+222,114
+129% +$151M 0.11% 167
2026
Q1 		$133M Sell
171,571
-23,124
-12% -$17.7M 0.07% 262
2025
Q4 		$150M Buy
194,695
+2,111
+1% +$1.43M 0.09% 228
2025
Q3 		$108M Buy
192,584
+186,521
+3,076% +$105M 0.07% 268
2025
Q2 		$3.18M Buy
+6,063
New +$3.38M ﹤0.01% 1314
2023
Q4 		– Sell
-2,262
Closed -$1.86M – 1536
2023
Q3 		$1.86M Hold
2,262
– – ﹤0.01% 873
2023
Q2 		$1.63M Buy
+2,262
New +$1.74M ﹤0.01% 883
2023
Q1 		– Sell
-1,661
Closed -$1.2M – 1488
2022
Q4 		$1.2M Buy
1,661
+656
+65% +$484K ﹤0.01% 987
2022
Q3 		$692K Sell
1,005
-177,537
-99% -$112M ﹤0.01% 1052
2022
Q2 		$106M Buy
178,542
+142,319
+393% +$92.5M 0.15% 147
2022
Q1 		$25.3M Buy
36,223
+31,609
+685% +$20M 0.03% 366
2021
Q4 		$2.91M Buy
+4,614
New +$2.84M ﹤0.01% 938
2021
Q1 		– Sell
-700
Closed -$338K – 2479
2020
Q4 		$338K Sell
700
-11,500
-94% -$6.21M ﹤0.01% 2098
2020
Q3 		$6.83M Buy
+12,200
New +$7.4M 0.01% 1005
2019
Q3 		– Sell
-403,526
Closed -$126M – 1684
2019
Q2 		$126M Buy
403,526
+93,195
+30% +$31M 0.28% 87
2019
Q1 		$127M Buy
310,331
+233,356
+303% +$96.1M 0.3% 62
2018
Q4 		$28.8M Buy
+76,975
New +$28.2M 0.08% 245
2018
Q1 		– Sell
-1,000
Closed -$376K – 1301
2017
Q4 		$376K Buy
+1,000
New +$405K ﹤0.01% 1106
2015
Q4 		– Sell
-40,069
Closed -$18.6M – 1567
2015
Q3 		$18.6M Sell
40,069
-31,336
-44% -$16.8M 0.09% 219
2015
Q2 		$36.4M Buy
+71,405
New +$34.8M 0.21% 119
2014
Q1 		– Sell
-31,466
Closed -$8.66M – 1303
2013
Q4 		$8.66M Buy
+31,466
New +$9.05M 0.05% 318

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Arrowstreet Capital's REGN Position: Q2 2026 in Review

Arrowstreet Capital increased its Regeneron Pharmaceuticals (REGN) stake by 129% in Q2 2026, buying an estimated $151M and bringing the position to 393,685 shares worth $245M. The position accounts for 0.11% of the portfolio, ranked #167.

Arrowstreet Capital first reported a position in REGN in Q4 2013 and has held it in 21 quarters since. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Arrowstreet Capital held 393,685 shares of Regeneron Pharmaceuticals worth $245M as of Q2 2026.
  • Arrowstreet Capital bought 222,114 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $151M.
  • Regeneron Pharmaceuticals made up 0.11% of Arrowstreet Capital's portfolio in Q2 2026, its #167 holding.
  • Arrowstreet Capital first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 21 quarters since.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.